Introduction
The management of advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations has evolved significantly over recent years. EGFR tyrosine kinase inhibitors (TKIs), particularly osimertinib, have become the cornerstone of first-line therapy due to their substantial efficacy and favorable safety profile. The recent phase 3 FLAURA2 trial has provided compelling evidence that combining osimertinib with platinum-based chemotherapy further extends overall survival (OS), marking a potential shift in treatment paradigms.